

# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/088,632	07/30/2002	Erik D'Hondt	B45201	7231
20462	7590 10/17/2006		EXAMINER	
	INE BEECHAM CORPO	MOSHER, MARY		
P. O. BOX	FE INTELLECTUAL PRO 1539	ART UNIT	PAPER NUMBER	
KING OF P	USSIA, PA 19406-0939		1648	
			DATE MAILED: 10/17/200	6

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Commons	10/088,632	D'HONDT ET AL.				
Office Action Summary	Examiner	Art Unit				
	Mary E. Mosher, Ph.D.	1648				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO  36(a). In no event, however, may a reply be tin  fill apply and will expire SIX (6) MONTHS from  cause the application to become ABANDONE	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 08 Au	Responsive to communication(s) filed on <u>08 August 2006</u> .					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E						
Disposition of Claims						
4) Claim(s) 26,27,29-35,41-44,46 and 51-56 is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s)is/are allowed.						
6)⊠ Claim(s) <u>26,29-35,41,42,44,46 and 51-56</u> is/are rejected.						
7)⊠ Claim(s) <u>27 and 43</u> is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examine	r.					
10)⊠ The drawing(s) filed on <u>20 March 2002</u> is/are: a)⊠ accepted or b)□ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the Ex		- · · · · · · · · · · · · · · · · · · ·				
Priority under 35 U.S.C. § 119						
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a)⊠ All b)□ Some * c)□ None of:						
3. Copies of the certified copies of the priori		•				
application from the International Bureau		sa iii iiiis Mational Glage				
* See the attached detailed Office action for a list of	. , ,	ed.				
	•	•				
Attachment(s)						
Notice of References Cited (PTO-892)	4) Interview Summary					
2)	Paper No(s)/Mail Da 5) Notice of Informal F					
Paper No(s)/Mail Date <u>8/8/2006</u> .	aton Application					

Art Unit: 1648

### **DETAILED ACTION**

## Claim Rejections - 35 USC § 112

Claims 26, 29-35, 41, 42, 44, 46, 51-56 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for whole virus vaccines, does not reasonably provide enablement for split virus vaccines. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. The 2006 publication by Bresson et al and the 2004 and 2002 publications by Hehme et all provide evidence that aluminum adjuvant improves the immunogenicity of whole-virus formulations but not split-virus formulations of potential pandemic influenza, for the doses recited in the claims. These publications provide the reasons, previously missing, to doubt the efficacy of the split-virus vaccine that is encompassed by the claims. Considering the limited teachings in the specification, and the subsequent showing that the claimed dose of spit-virus formulation is not sufficient to induce an adequate immune response, it is concluded that undue experimentation would be required to enable the full scope of the invention as claimed.

## Allowable Subject Matter

Claim 27, 43 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

The very recent publication by Lin et al (Lancet 368:991-997, 2006; available online September 7, 2006) is cited as of interest in confirming the immunogenicity of

Art Unit: 1648

aluminum adjuvanted, whole virus, H5N1 influenza at doses less than 15 ug hemagglutinin per dose.

### Conclusion

Applicant's submission of an information disclosure statement under 37 CFR 1.97(c) with the fee set forth in 37 CFR 1.17(p) on 8/8/2006 prompted the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS**MADE FINAL. See MPEP § 609.04(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary E. Mosher, Ph.D. whose telephone number is 571-272-0906. The examiner can normally be reached on varying dates and times; please leave a message..

Application/Control Number: 10/088,632

Art Unit: 1648

Page 4

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

10/14/06

MARY E. MOSHER, PH.D. PRIMARY EXAMINER